RANKL-RANK signaling regulates osteoblast differentiation and bone formation

References

[1] Lacey DL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93:165-176

[2] Kong YY et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development, and lymph-node organogenesis. Nature, 1999, 397:315-323

[3] Li J et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. U. S. A., 2000, 97:1566-1571

[4] Otsuki Y et al. W9 peptide enhanced osteogenic differentiation of human adipose-derived stem cells. Biochem. Biophys. Res. Commun., 2018, 495:904-910

[5] Uehara T et al. Delivery of RANKL-binding peptide OP3-4 promotes BMP-2-induced maxillary bone regeneration. J. Dent. Res., 2016, 95:665-672

[6] Portal-Nunez S et al. Unexpected bone formation produced by RANKL. Trends Endocrinol. Metab.: TEM, 2017, 28:695-704

[7] Furuya Y et al. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-kappaB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity. J. Biol. Chem., 2013, 288:5562-5571

[8] Ikebuchi Y et al. Coupling of bone resorption and formation by RANKL reverse signalling. Nature, 2018, 561:195-200